Bausch Health Companies (NYSE:BHC – Get Rating) had its price objective decreased by stock analysts at Bank of America from $25.00 to $12.00 in a research note issued on Wednesday, The Fly reports. Bank of America‘s target price would suggest a potential upside of 27.66% from the stock’s previous close.
A number of other equities analysts have also recently commented on the company. Royal Bank of Canada lowered their price target on Bausch Health Companies from $32.00 to $21.00 and set an “outperform” rating for the company in a report on Monday. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Tuesday, March 29th. Finally, TheStreet downgraded shares of Bausch Health Companies from a “c-” rating to a “d+” rating in a research note on Monday, March 28th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Bausch Health Companies currently has a consensus rating of “Buy” and an average target price of $23.25.
Shares of NYSE BHC opened at $9.40 on Wednesday. The stock has a market capitalization of $3.39 billion, a P/E ratio of -3.53, a PEG ratio of 0.31 and a beta of 1.62. Bausch Health Companies has a 52 week low of $7.80 and a 52 week high of $32.54. The stock’s fifty day moving average is $21.59 and its 200 day moving average is $24.34.
In other news, insider Robert Spurr sold 1,595 shares of the stock in a transaction dated Thursday, April 14th. The stock was sold at an average price of $22.19, for a total value of $35,393.05. Following the completion of the sale, the insider now owns 90,506 shares of the company’s stock, valued at $2,008,328.14. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joseph F. Gordon sold 3,889 shares of Bausch Health Companies stock in a transaction that occurred on Tuesday, March 8th. The stock was sold at an average price of $21.76, for a total value of $84,624.64. The disclosure for this sale can be found here. Insiders have sold a total of 16,668 shares of company stock worth $378,570 over the last three months. Insiders own 13.75% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Amplius Wealth Advisors LLC acquired a new position in shares of Bausch Health Companies in the 4th quarter valued at about $30,000. Glassman Wealth Services increased its holdings in Bausch Health Companies by 71.4% in the fourth quarter. Glassman Wealth Services now owns 1,152 shares of the company’s stock worth $32,000 after purchasing an additional 480 shares in the last quarter. WASHINGTON TRUST Co acquired a new position in Bausch Health Companies in the first quarter valued at approximately $28,000. Creative Financial Designs Inc. ADV boosted its holdings in shares of Bausch Health Companies by 525.0% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company’s stock worth $29,000 after buying an additional 1,050 shares in the last quarter. Finally, Moors & Cabot Inc. bought a new stake in shares of Bausch Health Companies in the 3rd quarter valued at $228,000. 73.38% of the stock is currently owned by institutional investors and hedge funds.
Bausch Health Companies Company Profile (Get Rating)
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.